News >

Palbociclib/Cetuximab Combo Highly Active in HPV-Unrelated HNSCC

Jason Harris
Published: Monday, Jul 09, 2018

Douglas R. Adkins, MD

Douglas R. Adkins, MD

The combination of the CDK4/6 inhibitor palbociclib (Ibrance) and cetuximab (Erbitux) induced an overall response rate of 39% in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), according to results presented at the 2018 ASCO Annual Meeting.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x